PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Envigo opens its doors for business on 21 September

Envigo has been created through the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates.
 
Huntingdon (UK), 21 September, 2015: Huntingdon Life Sciences, Harlan Laboratories and three subsidiaries have announced that the combined companies have today re-branded as Envigo (pronounced En-vee-go.).
Brian Cass, CEO, commented: “Today we are delighted to officially re-brand as Envigo. This marks a significant milestone for the five companies that came together to create Envigo and demonstrates the great progress we have made in our integration. Our customers are increasingly seeking partners who can deliver a variety of services in a co-ordinated manner, and the breadth of Envigo’s offering strengthens our ability to deliver on that need.”
 
Envigo employs 3,800 people and has sales approaching $500 million.  The company is a top-three provider of non-clinical research services and research models and services to the pharmaceutical, chemical and crop protection industries, as well as academic institutions and government agencies worldwide.
Since the announcement on 24 June 2015 that the five companies were combining to form Envigo customers have shown their support for the new company. Adrian Hardy, COO, added: “We have received very positive comments from customers to the on-going integration of our businesses and to our new name. Today we have become Envigo, and our goal is to establish the company as the number one partner for both customer service and scientific excellence.”
 
Notes to editors
Envigo is a privately-held global company that provides essential non-clinical contract research services, research models and services, animal diets and products to the biopharmaceutical, crop protection and chemical industries, universities, government, and other research organizations.
The company is committed to helping customers realize the full potential of their research and products which contribute to enhancing the lives of people and animals as well as protecting the environment.
www.envigo.com
 
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com  / t.jervis@defacto.com

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026